High-risk cutaneous squamous cell carcinoma: a review of current evidence and emerging standards
Cemiplimab redefines the post-operative standard; pembrolizumab awaits confirmation. Future directions include earlier immunotherapy, biomarker validation and access expansion.
Authors
- F. Petrelli
- Daniela Carioli
- Elisa Dal Cin (ORCID: https://orcid.org/0000-0001-5990-1004)
- Massimiliano Nardone
- Vincenzo Capriotti (ORCID: https://orcid.org/0000-0001-5294-0449)
- Chiara Bramati (ORCID: https://orcid.org/0000-0002-0765-781X)
- Angela Gasparini
- Daniele Spada
Institutions
- University of Bergamo (IT)
- Ospedale di Mirano (IT)
- Azienda Socio Sanitaria Territoriale di Bergamo Ovest
Publication Details
- Journal
- The Journal of Laryngology & Otology
- Published
- 2026-01-19
- DOI
- https://doi.org/10.1017/s0022215126104332
- Primary Topic
- Nonmelanoma Skin Cancer Studies
- Type
- article
- Field-Weighted Citation Impact
- 0.00